- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02684799
Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
November 21, 2017 updated by: Tobira Therapeutics, Inc.
A Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole (OME) and Famotidine (FAM), on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC)
This is a Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole and Famotidine, on the PK of CVC
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33126
- SeaView Research, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be informed of the nature of the study and have provided written informed voluntary consent.
- Have a BMI ≥ 18.0 and ≤ 35.0 kg/m2.
- Be in good general health with no clinically relevant abnormalities based on medical history, physical examination, clinical laboratory evaluations (clinical chemistry, hematology, urinalysis), and 12-lead ECG that, in the opinion of the Investigator, would affect subject safety.
- Be able to communicate effectively with the Investigator and other study center personnel and agree to comply with the study procedures and restrictions.
Exclusion Criteria:
- Any disease or condition that might affect drug absorption, metabolism, or excretion, or clinically significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease, as determined by the Investigator and, if necessary, the Sponsor's Medical Monitor.
- History of stomach or intestinal surgery, except for fully healed appendectomy and/or cholecystectomy which will be allowed.
- Clinically significant illness or clinically significant surgery within 4 weeks before the administration of study medication.
- History of GERD, heartburn, or nausea more than once a month, or any similar symptoms requiring the regular use of antacids, or any use of H2 histamine blockers or proton-pump inhibitors over the past 3 months.
- History of achlorhydria, pernicious anemia, or peptic ulcers over the past 6 months.
- Have a positive Helicobacter pylori urea breath test.
- Known or suspected hypersensitivity or allergic reaction to any of the components of CVC, OME or FAM tablets.
- History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin.
- If female, is pregnant or breast feeding, or has a positive pregnancy test result prior to the first dose of study medication.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Part 1 Group 1 (Cenicriviroc)
Part 1 Group 1 (12 subjects) will receive CVC 150 mg on Days 1, 7 and 13.
|
Other Names:
|
|
Active Comparator: Part 1 Group 1 (Omeprazole)
Part 1 Group 1 (12 subjects) will receive Omeprazole 20 mg from Days 2-7, and Omeprazole 40 mg from Days 8-13.
|
Other Names:
|
|
Experimental: Part 1 Group 2 (Cenicriviroc)
Part 1 Group 2 (12 subjects) will receive CVC 150 mg on Days 1, 5, 9 and 13.
|
Other Names:
|
|
Active Comparator: Part 1 Group 2 (Famotidine)
Part 1 Group 2 (12 subjects) will receive Famotidine 40 mg on Days 5, 9 and 13.
|
Other Names:
|
|
Experimental: Part 2 (Cenicriviroc)
Part 2 (24 subjects) will receive Cenicriviroc from Days 1-10 and Days 11-20.
|
Other Names:
|
|
Active Comparator: Part 2 (Omeprazole)
Part 2 (24 subjects) will receive Omeprazole from Days 11-20.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pharmacokinetic Assessment of CVC, as measured by maximum plasma concentration (Cmax)
Time Frame: Days 1, 7, and 13 for Part 1 Group 1. Days 1, 5, 9, and 13 for Part 1 Group 2.
|
Days 1, 7, and 13 for Part 1 Group 1. Days 1, 5, 9, and 13 for Part 1 Group 2.
|
|
Pharmacokinetic Assessment of CVC, as measured by minimum plasma concentration (Cmin)
Time Frame: Days 1, 7, and 13 for Part 1 Group 1. Days 1, 5, 9, and 13 for Part 1 Group 2.
|
Days 1, 7, and 13 for Part 1 Group 1. Days 1, 5, 9, and 13 for Part 1 Group 2.
|
|
Pharmacokinetic Assessment of CVC, as measured by area under the plasma concentration-time curve (AUC)
Time Frame: Days 1, 7, and 13 for Part 1 Group 1. Days 1, 5, 9, and 13 for Part 1 Group 2.
|
Days 1, 7, and 13 for Part 1 Group 1. Days 1, 5, 9, and 13 for Part 1 Group 2.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of Adverse Events
Time Frame: 23 days
|
Evaluate adverse events
|
23 days
|
|
Changes from Baseline in 12-lead ECGs
Time Frame: Baseline and 23 days
|
Evaluate changes from baseline in 12-lead ECGs
|
Baseline and 23 days
|
|
Changes from Baseline in Vital Signs
Time Frame: Baseline and 23 days
|
Evaluate changes from baseline in vital signs, including blood pressure and pulse rate
|
Baseline and 23 days
|
|
Changes from Baseline in Physical Examinations
Time Frame: Baseline and 23 days
|
Evaluate changes from baseline in physical examinations
|
Baseline and 23 days
|
|
Changes from Baseline in Clinical Laboratory Tests
Time Frame: Baseline and 23 days
|
Evaluate changes from baseline in clinical laboratory tests including serum chemistry, hematology and urinalysis
|
Baseline and 23 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Star Seyedkazemi, PharmD, Tobira Therapeutics, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 31, 2016
Primary Completion (Actual)
April 11, 2016
Study Completion (Actual)
April 11, 2016
Study Registration Dates
First Submitted
February 3, 2016
First Submitted That Met QC Criteria
February 17, 2016
First Posted (Estimate)
February 18, 2016
Study Record Updates
Last Update Posted (Actual)
November 24, 2017
Last Update Submitted That Met QC Criteria
November 21, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Histamine Antagonists
- Histamine Agents
- CCR5 Receptor Antagonists
- Histamine H2 Antagonists
- Famotidine
- Omeprazole
- Cenicriviroc
Other Study ID Numbers
- 652-123
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.